Venetoclax for Chronic Lymphocytic Leukemia

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Chronic Lymphocytic Leukemia+1 MoreVenetoclax - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new combo treatment for CLL/SLL to see how effective it is at getting rid of disease.

Eligible Conditions
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Leukemia

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 1 year

1 year
establish the rate of minimum residual disease (MRD) undetectable response

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

BOVEN regimen
1 of 1

Experimental Treatment

127 Total Participants · 1 Treatment Group

Primary Treatment: Venetoclax · No Placebo Group · Phase 2

BOVEN regimenExperimental Group · 3 Interventions: Obinutuzumab, Venetoclax, Zanubrutinib · Intervention Types: Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Obinutuzumab
FDA approved
Venetoclax
FDA approved
Zanubrutinib
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

Roche-GenentechIndustry Sponsor
21 Previous Clinical Trials
2,517 Total Patients Enrolled
Massachusetts General HospitalOTHER
2,699 Previous Clinical Trials
30,843,035 Total Patients Enrolled
BeiGene USA, Inc.Industry Sponsor
2 Previous Clinical Trials
194 Total Patients Enrolled
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,832 Previous Clinical Trials
584,290 Total Patients Enrolled
Andrew Zelenetz, MD, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
4 Previous Clinical Trials
209 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: